Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hematopoietic cell-specific Lyn substrate 1 (HCLS1)
- Target
- HCLS1
- Molecular classification
- Other (Actin-binding/adaptor protein), Signaling adaptor protein
01
Overview
Hematopoietic cell-specific Lyn substrate 1 (HCLS1, also known as HS1) is an intracellular, actin-binding adaptor protein primarily expressed in hematopoietic cells. It is a cytoskeletal regulator closely related to cortactin, functioning by promoting dynamic actin remodeling required for leukocyte migration, antigen receptor signaling, adhesion, and immune synapse formation. HCLS1 mediates downstream signaling from multiple immune receptors, including the B-cell receptor (BCR), T-cell receptor (TCR), and chemokine receptor CXCR4. Altered HCLS1 expression or phosphorylation state is associated with various pathologies, including leukemia and altered immune responses; its low expression in lung adenocarcinoma correlates with poor prognosis and reduced immune cell infiltration. Commonly used as a biomarker in immune-oncology research, HCLS1 is not currently a direct drug target but remains of significant research interest for its roles in immunity and cancer biology.[1][3][5]
- Other names
- HS1Hematopoietic cell-specific protein 1
02
Mechanism of action
No approved drugs; thus, drug-specific mechanism unknown
03
Biological functions
Signal transductionRegulation of actin cytoskeletonImmune responseCell migrationRegulation of gene expression
04
Disease associations
Cancer (including leukemia and lung adenocarcinoma)Immune disorders (e.g., Wiskott-Aldrich Syndrome)Other (Frank-Ter Haar Syndrome)
05
Safety considerations
Potentially involved in regulation of immune synapses and cell motility; precise safety issues for therapeutic targeting are not established, but disruption could affect immune function[1][3]
06
Biomarkers
Prognostic biomarker for lung adenocarcinoma (LUAD)[3]Potential biomarker for immune infiltration and prognosis in certain leukemias[3]
Beyond the preview
Go deeper on Hematopoietic cell-specific Lyn substrate 1 (HCLS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hematopoietic cell-specific Lyn substrate 1 (HCLS1).